IL317899A - Stabilized formulations containing anti-IL–33 antibodies - Google Patents

Stabilized formulations containing anti-IL–33 antibodies

Info

Publication number
IL317899A
IL317899A IL317899A IL31789924A IL317899A IL 317899 A IL317899 A IL 317899A IL 317899 A IL317899 A IL 317899A IL 31789924 A IL31789924 A IL 31789924A IL 317899 A IL317899 A IL 317899A
Authority
IL
Israel
Prior art keywords
antibodies
formulations containing
containing anti
stabilized formulations
stabilized
Prior art date
Application number
IL317899A
Other languages
English (en)
Hebrew (he)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL317899A publication Critical patent/IL317899A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Environmental & Geological Engineering (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
IL317899A 2019-03-21 2020-03-20 Stabilized formulations containing anti-IL–33 antibodies IL317899A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821661P 2019-03-21 2019-03-21
PCT/US2020/023795 WO2020191270A1 (fr) 2019-03-21 2020-03-20 Formulations stabilisées contenant des anticorps anti-il-33

Publications (1)

Publication Number Publication Date
IL317899A true IL317899A (en) 2025-02-01

Family

ID=70228884

Family Applications (2)

Application Number Title Priority Date Filing Date
IL317899A IL317899A (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-IL–33 antibodies
IL286024A IL286024B2 (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-IL–33 antibodies

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL286024A IL286024B2 (en) 2019-03-21 2020-03-20 Stabilized formulations containing anti-IL–33 antibodies

Country Status (19)

Country Link
US (2) US11596690B2 (fr)
EP (1) EP3941522A1 (fr)
JP (2) JP7695887B2 (fr)
KR (1) KR20210141592A (fr)
CN (3) CN113573733B (fr)
AU (1) AU2020241882A1 (fr)
BR (1) BR112021018727A2 (fr)
CA (1) CA3133995A1 (fr)
CL (1) CL2021002440A1 (fr)
CO (1) CO2021011648A2 (fr)
EA (1) EA202192568A1 (fr)
IL (2) IL317899A (fr)
MA (1) MA55362A (fr)
MX (1) MX2021011137A (fr)
PH (1) PH12021552092A1 (fr)
SA (1) SA521430229B1 (fr)
SG (1) SG11202109822XA (fr)
TW (2) TWI861073B (fr)
WO (1) WO2020191270A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
WO2021228760A1 (fr) * 2020-05-11 2021-11-18 Medimmune Limited Formulations d'anticorps anti-il-33
CN113603775B (zh) 2021-09-03 2022-05-20 江苏荃信生物医药股份有限公司 抗人白介素-33单克隆抗体及其应用
WO2023077685A1 (fr) * 2021-11-04 2023-05-11 江苏荃信生物医药股份有限公司 Procédé de préparation d'une solution concentrée comprenant un anticorps monoclonal contre l'interleukine-33 humaine et préparation liquide
CN113842457B (zh) * 2021-11-04 2022-05-20 江苏荃信生物医药股份有限公司 包含抗人白介素-33单克隆抗体的液体制剂
WO2026067832A1 (fr) * 2024-09-30 2026-04-02 深圳市小分子新药创新中心有限公司 Anticorps à domaine unique anti-il-33 et dérivé de celui-ci

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
GB2361704C (en) * 2000-03-03 2006-08-02 Cambridge Antibody Tech Human antibodies against eotaxin and their use
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GB0600351D0 (en) * 2006-01-10 2006-02-15 Weston Terence E Safe hypodermic needle
US8119771B2 (en) 2007-04-26 2012-02-21 The Provost, Fellow and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth, Near Dublin Products for altering IL-33 activity and methods thereof
JP2010527936A (ja) 2007-05-18 2010-08-19 メディミューン，エルエルシー 炎症性疾患におけるｉｌ−３３
EP2475388B1 (fr) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Utilisation d'antagonistes de l'il-33 à des fins de traitement des maladies fibrotiques
MX366337B (es) * 2010-10-06 2019-07-05 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r).
WO2013059524A2 (fr) * 2011-10-18 2013-04-25 Emory University Anticorps antigrippaux
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
CN118286417A (zh) * 2012-09-07 2024-07-05 瑞泽恩制药公司 以il-4r拮抗剂治疗特应性皮炎的方法
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
JP6858182B2 (ja) * 2015-10-06 2021-04-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． インターロイキン３３（ｉｌ−３３）媒介疾患に関するバイオマーカーおよびその使用
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
NZ757965A (en) 2017-03-16 2022-07-01 Lg Chemical Ltd Liquid formulation of anti-tnf alpha antibody
EP3966227A1 (fr) * 2019-05-07 2022-03-16 Voyager Therapeutics, Inc. Compositions et méthodes d'augmentation vectorisée de la destruction, de l'expression et/ou de la régulation de protéines
CN112851814B (zh) * 2020-03-17 2023-07-07 西安宇繁生物科技有限责任公司 一种靶向bcma的全人源单链抗体及其制备方法与应用
EP4255451A4 (fr) * 2020-12-03 2025-01-01 The Board Of Regents Of The University Of Texas System Méthodes d'identification d'anticorps bloquant lilrb
TW202237639A (zh) * 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法

Also Published As

Publication number Publication date
US20200297845A1 (en) 2020-09-24
IL286024A (en) 2021-10-31
KR20210141592A (ko) 2021-11-23
WO2020191270A1 (fr) 2020-09-24
EP3941522A1 (fr) 2022-01-26
SG11202109822XA (en) 2021-10-28
IL286024B1 (en) 2025-01-01
PH12021552092A1 (en) 2022-05-30
CA3133995A1 (fr) 2020-09-24
BR112021018727A2 (pt) 2022-02-15
MX2021011137A (es) 2021-10-22
CO2021011648A2 (es) 2021-09-30
CN119700966A (zh) 2025-03-28
CN113573733B (zh) 2024-12-31
AU2020241882A1 (en) 2021-10-14
JP2022526292A (ja) 2022-05-24
TWI861073B (zh) 2024-11-11
SA521430229B1 (ar) 2024-01-23
TW202519263A (zh) 2025-05-16
US11596690B2 (en) 2023-03-07
CN113573733A (zh) 2021-10-29
EA202192568A1 (ru) 2021-12-03
US20230346929A1 (en) 2023-11-02
CN119700965A (zh) 2025-03-28
MA55362A (fr) 2022-01-26
IL286024B2 (en) 2025-05-01
JP7695887B2 (ja) 2025-06-19
JP2025131756A (ja) 2025-09-09
CL2021002440A1 (es) 2022-04-22
TW202102260A (zh) 2021-01-16

Similar Documents

Publication Publication Date Title
IL288153A (en) Stabilized formulations containing anti-angptl3 antibodies
IL286100A (en) Formulations of anti-il-36r antibodies
IL291068A (en) Anti-cd73 antibodies
IL289112A (en) Antibodies against tigit
SG11202109822XA (en) Stabilized formulations containing anti-il-33 antibodies
IL291131A (en) Anti-il-23p19 antibody formulations
GB201905150D0 (en) Ant-ige antibodies
IL290141A (en) Anti-pvrig antibodies formulations and uses thereof
SI4076385T1 (sl) Formulacije protiteles anti-pd1
IL276626A (en) Formulations of B7-H4 antibody
IL279865A (en) A new stable high concentration formulation for anti-FXIa antibodies
IL284584A (en) Anti-tigit antibodies
GB201809976D0 (en) Novel formulations
SG11202102875YA (en) Anti-fgfr2 antibody formulations
SG11202104012QA (en) Antibody formulations
IL287224A (en) New formulations containing melphalan
IL290356A (en) Formulations for Resotide
GB201904338D0 (en) Fluorouracil-containing formulations
IL284691A (en) formulations
GB201917480D0 (en) Antibodies
GB201900732D0 (en) Antibodies
ZA202006262B (en) Stable antibody formulation
IL310275A (en) Antibody formulations
IL289160A (en) Anti-angpt2 antibodies
IL299152A (en) Stabilized formulations that include antibodies against CTLA-4